Summit Therapeutics Inc. (SMMT) News
Track canonical SquawkNews coverage tagged to SMMT, Summit Therapeutics Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 28 indexed stories across 14 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Summit Therapeutics presents updated HARMONi OS data showing consistent survival benefit with ivonescimab; BLA PDUFA Nov 14, 2026
Summit Therapeutics announced updated HARMONi Phase III overall survival results showing a consistent OS benefit for ivonescimab plus chemotherapy versus placebo plus chemotherapy.Key Highlights:Original SEC Filing: Summ
REGULATION | Sep 15, 2026, 12:55 PM UTC
L
Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients
Summit Therapeutics Inc. (Nasdaq: SMMT) announced that updated overall survival (OS) results from the global Phase III HARMONi clinical trial featuring the novel, potential first-in-class investigational bispecific antib
NEWS | Sep 15, 2026, 10:00 AM UTC
L
Summit’s ivonescimab cuts death risk by 27% versus Keytruda in lung cancer trial
Summit Therapeutics NASDAQ:SMMT on Sunday said ivonescimab significantly extended survival compared with Merck’s NYSE:MRK Keytruda in a late-stage lung cancer trial conducted by its partner Akeso OTC:AKESF in China.Ivone
GEOPOLITICS | Sep 13, 2026, 05:23 PM UTC
L
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China
Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. announced that updated data, including overall survival (OS), from the randomized, double-blind Phase III HARMONi-2 trial featuring the nove
GEOPOLITICS | Sep 13, 2026, 11:00 AM UTC
L
Jefferies upgrades Summit Therapeutics to Buy from Hold
Benzinga (via TradingView News) reports Jefferies raised its rating on Summit Therapeutics from Hold to Buy.
EQUITY | Sep 09, 2026, 09:32 PM UTC
L
UK new car registrations rise 13.7% year-on-year to 94,236
Society of Motor Manufacturers and Traders data shows UK new car registrations up 13.7% year-on-year to 94,236 units, the ninth straight month of growth. Private registrations rose 19.0%.
EQUITY | Sep 04, 2026, 12:06 PM UTC
M
Summit Therapeutics stock jumps as ivonescimab extends survival in China
Shares of Summit Therapeutics rose more than 12% Thursday morning after the company said ivonescimab is extending survival in a Chinese lung cancer study, lifting the stock to $16.46.
EQUITY | Sep 03, 2026, 04:00 PM UTC
M
Summit notes Akeso reported OS benefit in HARMONi-2
Summit Therapeutics said partner Akeso reported ivonescimab achieved a statistically significant overall survival benefit versus pembrolizumab in the Phase III HARMONi-2 study.
REGULATION | Sep 03, 2026, 01:23 PM UTC
M
SMMT ivonescimab shows statistically significant OS benefit vs pembrolizumab
SMMT reports ivonescimab monotherapy showed a statistically significant overall survival benefit versus pembrolizumab monotherapy in PD-L1-positive advanced NSCLC in the HARMONi-2 study.
GEOPOLITICS | Sep 02, 2026, 09:42 PM UTC
M
HARMONi-2 study shows OS benefit for ivonescimab monotherapy vs pembrolizumab
Summit Therapeutics said Akeso announced positive overall survival results from the Phase III HARMONi-2 randomized, double-blind study comparing ivonescimab and pembrolizumab monotherapy in PD-L1-positive advanced NSCLC.
GEOPOLITICS | Sep 02, 2026, 09:41 PM UTC
L
Summit trials gain credibility after Akeso Phase 3 data, Guggenheim says
Guggenheim said Summit’s global lung cancer trials gained credibility following Akeso’s Phase 3 data, per TradingView News.
EQUITY | Aug 26, 2026, 05:51 PM UTC
L
Summit Therapeutics flags OS superiority for ivonescimab Phase III
TradingView News reports Summit Therapeutics says its ivonescimab regimen shows OS superiority in Phase III HARMONi-GI1.
EQUITY | Aug 26, 2026, 01:24 PM UTC
M
Ivonescimab plus chemotherapy reports overall survival benefit in trial
SMMT said Ivonescimab plus chemotherapy showed a statistically significant overall survival benefit versus durvalumab plus chemotherapy in first-line advanced biliary tract cancer in a single-region trial in China.
GEOPOLITICS | Aug 25, 2026, 10:08 PM UTC
L
SMMT publishes Phase III HARMONi analysis in Lancet Oncology
SMMT publishes primary analysis results from its global Phase III HARMONi study of ivonescimab plus chemotherapy in The Lancet Oncology.
EQUITY | Aug 25, 2026, 11:07 AM UTC
H
SMMT: Ivonescimab Approved in China
SMMT's Ivonescimab is approved in China for first-line treatment of squamous non-small cell lung cancer
EQUITY | Aug 12, 2026, 01:26 PM UTC
M
Multiple Stocks Upgraded
Several stocks receive upgrades from various analysts
EQUITY | Aug 12, 2026, 10:47 AM UTC
M
Summit Therapeutics Expands Ivonescimab Program
Summit Therapeutics starts new cancer study
EQUITY | Aug 05, 2026, 11:08 AM UTC
H
Alpha Buying: When a CEO Spends $5 Million on His Own Stock, Pay Attention
Corporate executives say optimistic things about their companies every day. They appear on earnings calls, investor presentations and financial television programs to explain why the latest disappointing quarter is merel
EARNINGS | Jul 24, 2026, 07:29 PM UTC
H
Deckers Outdoor, Summit Therapeutics, Robert Half And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Friday. Shares of Deckers Outdoor Cor p (NYSE: DECK ) fell sharply in pre-market trading after the company reported first-qua
EARNINGS | Jul 24, 2026, 12:04 PM UTC
H
Closing Bell Movers: Intel up 4% on Q2 earnings beat
Mega-cap Tech weighed heavily on sentiment in Thursday's trading as elevated capex plans by Alphabet (GOOGL) and Tesla (TSLA) worried investors. Parent of Google fell 7% to trade at a 3-month lows, while Tesla shed 15%,
RATES | Jul 24, 2026, 12:02 AM UTC
L
SMMT Summit Therapeutics - to offer and sell common stock up to $380M aggregate through sales agent - SEC filing
SMMT Summit Therapeutics - to offer and sell common stock up to $380M aggregate through sales agent - SEC filing
REGULATION | Jul 23, 2026, 08:35 PM UTC
L
Summit Therapeutics reports Q2 EPS (28c), consensus (21c)
"The clinical...
EQUITY | Jul 23, 2026, 08:10 PM UTC
L
RHI -10.4%, FIX -3.6%, SMMT -3%, SKYW -2.7%, SCHL -2.5% after results
RHI -10.4%, FIX -3.6%, SMMT -3%, SKYW -2.7%, SCHL -2.5% after results
EQUITY | Jul 23, 2026, 08:10 PM UTC
L
SMMT Summit Therapeutics RESULTS: Q2, Q2 EPS $-0.28, Q2 Net Income $-215.7M, Q2 operating expenses $220.5M
SMMT Summit Therapeutics RESULTS: Q2, Q2 EPS $-0.28, Q2 Net Income $-215.7M, Q2 operating expenses $220.5M
EARNINGS | Jul 23, 2026, 08:06 PM UTC
H
Summit Therapeutics options imply 6.5% move in share price post-earnings
Summit Therapeutics options imply 6.5% move in share price post-earnings
EARNINGS | Jul 23, 2026, 05:50 PM UTC
L
serial disappointer risk (missed last 2 qtrs) in EPS reporters tonight and tomorrow morning - GBCI, SMMT, FRBA, WRLD, LBTYK, EAF
serial disappointer risk (missed last 2 qtrs) in EPS reporters tonight and tomorrow morning - GBCI, SMMT, FRBA, WRLD, LBTYK, EAF
EARNINGS | Jul 23, 2026, 04:28 PM UTC
L
SMMT +1.85% in pre-mkt trading - earlier PR: Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western a
SMMT +1.85% in pre-mkt trading - earlier PR: Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study Link T
EQUITY | Jul 22, 2026, 12:42 PM UTC
L
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at on our options activity scanner. Traders often look for
EQUITY | Jul 01, 2026, 05:35 PM UTC